Cologuard Plus is a noninvasive, stool-based DNA screening test designed to detect both colorectal cancer and advanced precancerous lesions In the pivotal BLUE-C study, Cologuard Plus ...
New powder combines 30 grams of high‑quality protein to help build muscle tissue,† 5 grams of creatine monohydrate to support ...
Announcement follows receipt of all regulatory clearances necessary for closing Transaction enables Abbott to enter and lead in fast-growing cancer screening and diagnostics segments, serving millions ...
- Ultreon™ 1.0 Software, the first-of-its-kind imaging software, merges optical coherence tomography with the power of automation using Artificial Intelligence - The new intuitive interface provides ...
The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information." Reflects the net tax benefit associated with the ...
The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information." Restructuring and cost reduction initiative ...
ABBOTT PARK, Ill., Aug. 19, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that it has completed its acquisition of OptiMedica Corporation, a privately-held, Silicon Valley-based ophthalmic ...
Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $101 million of ...
2021 Taxes on Earnings includes the recognition of approximately $40 million of net tax benefits as a result of the resolution of various tax positions related to prior years and approximately $45 ...
The table above provides additional details regarding the specified items described on tables titled "Non-GAAP Reconciliation of Financial Information." Restructuring and cost reduction initiative ...
2020 Tax expense on Earnings from Continuing Operations includes the recognition of approximately $135 million of tax benefits related to the impairment of certain assets, approximately $25 million of ...
Libre Duo 10 Day is a first-of-its-kind, two-in-one biowearable that monitors glucose and helps detect rising ketone levels that can lead to diabetic ketoacidosis (DKA), a serious health condition for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results